CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab

CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab

The CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab is a highly specialized molecular diagnostic assay designed to detect somatic mutations within exon 9 of the calreticulin (CALR) gene. This test is of paramount clinical importance in the modern diagnostic algorithm for myeloproliferative neoplasms (MPNs), specifically essential thrombocythemia (ET) and primary myelofibrosis (PMF). Calreticulin is a multi-functional, calcium-binding chaperone protein primarily localized in the lumen of the endoplasmic reticulum. Somatic insertions or deletions (indels) within exon 9 of the CALR gene alter the C-terminal domain of the protein, leading to the activation of the thrombopoietin receptor (MPL) and the downstream JAK-STAT signaling pathway. This aberrant activation drives the uncontrolled clonal proliferation of megakaryocytes and platelets, which is the hallmark of MPNs.

At Chughtai Lab, this molecular evaluation is performed utilizing state-of-the-art polymerase chain reaction (PCR) and fragment analysis or next-generation sequencing (NGS) methodologies. The inclusion of the "Form NIBD" protocol ensures seamless collaboration and clinical correlation with the National Institute of Blood Diseases, establishing a standardized framework for hematopathological interpretation. This test holds immense diagnostic value, particularly for patients who present with clinical features of MPNs but test negative for the JAK2 V617F mutation. Identifying a CALR mutation not only confirms a clonal hematological disorder but also assists clinicians in distinguishing primary myeloproliferative conditions from reactive states, such as secondary thrombocytosis. Furthermore, the specific molecular subtype of the CALR mutation provides critical prognostic insights that guide therapeutic decisions and risk stratification.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and specimen integrity for the CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab, patients should adhere to the following preparation guidelines:

• No Fasting Required: Fasting is not medically necessary for this molecular genetic test. Patients may consume food and liquids normally prior to sample collection.
• Medication Documentation: Patients must inform the laboratory staff of all current medications, especially cytoreductive therapies, anticoagulants, or chemotherapy, as these can influence overall clinical correlation.
• Clinical History and Form NIBD: It is mandatory to present the completed NIBD referral form along with relevant clinical history, complete blood count (CBC) reports, and bone marrow biopsy findings if available.
• Hydration: Adequate hydration is recommended prior to the blood draw to facilitate easier venous access.

During the Procedure

The collection of the specimen for the CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab follows a strict clinical protocol to maintain sample viability and prevent contamination:

• Patient Identification and Verification: The phlebotomist will verify the patient's identity using at least two independent identifiers and confirm that the NIBD clinical form is properly filled out.
• Specimen Collection: A peripheral blood sample is obtained via standard venipuncture from a vein in the arm. In certain clinical scenarios, a bone marrow aspirate sample may be utilized if collected by a hematologist.
• Tube Type: The blood sample is collected into an EDTA (lavender top) tube, which preserves the cellular DNA required for molecular analysis.
• Aseptic Technique: The venipuncture site is thoroughly cleansed with an antiseptic solution to prevent external bacterial or environmental DNA contamination.
• Duration and Experience: The blood draw takes approximately 2 to 5 minutes. Patients may feel a mild, brief prick as the needle is inserted.
• Post-Collection Care: Gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a bandage to prevent bruising.
• Laboratory Transport: The specimen is immediately labeled with unique barcoded identifiers and transported to the specialized molecular pathology department under controlled temperature conditions.

When is a CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab Performed?

Investigation of Unexplained Thrombocytosis

Physicians request this test when a patient presents with a persistently elevated platelet count (thrombocytosis) exceeding 450 x 10^9/L without an obvious reactive cause, such as iron deficiency, chronic inflammation, or active infection. The assay helps confirm whether the elevated platelet level is due to a clonal stem cell disorder like essential thrombocythemia.

Evaluation of Suspected Primary Myelofibrosis

This molecular test is indicated when clinical and radiological findings suggest primary myelofibrosis. Symptoms such as unexplained splenomegaly, hepatomegaly, severe constitutional symptoms (night sweats, weight loss, bone pain), and blood smear findings of leukoerythroblastosis warrant this investigation to identify the underlying genetic driver.

Diagnostic Workup for JAK2-Negative Myeloproliferative Neoplasms

In the diagnostic algorithm for MPNs, the JAK2 V617F mutation is typically evaluated first. If the JAK2 mutation is absent (wild-type), testing for CALR exon 9 mutations is the critical next step. Approximately 20% to 25% of patients with essential thrombocythemia and primary myelofibrosis who are JAK2-negative will harbor a CALR mutation.

Prognostic Stratification in Hematological Malignancies

Identifying a CALR mutation is essential for determining the patient's long-term prognosis. Patients with CALR-mutated essential thrombocythemia generally experience a lower risk of thrombotic events and a more favorable overall survival rate compared to those with JAK2-mutated or triple-negative (JAK2, CALR, and MPL wild-type) disease.

Monitoring Post-Treatment Minimal Residual Disease

This highly sensitive molecular assay is performed periodically to monitor the patient's response to therapeutic interventions, such as interferon-alpha, JAK inhibitors, or allogeneic stem cell transplantation. Tracking the quantitative allelic burden of the CALR mutation helps clinicians assess treatment efficacy and detect early molecular relapse.

What Does a CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab Detect?

The CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab is designed to detect, characterize, and quantify several molecular and clinical parameters:

• Presence of Type 1 CALR mutation (a specific 52-base pair deletion, c.1092_1143del).
• Presence of Type 2 CALR mutation (a specific 5-base pair insertion, c.1154_1155insTTGTC).
• Atypical or variant CALR exon 9 insertions and deletions (indels) other than Type 1 and Type 2.
• The precise nucleotide sequence alterations within exon 9 of the calreticulin gene.
• The mutant allele burden, representing the proportion of mutated alleles relative to wild-type alleles.
• Clonal hematopoiesis associated with myeloproliferative neoplasms.
• Molecular confirmation of Essential Thrombocythemia (ET).
• Molecular confirmation of Primary Myelofibrosis (PMF).
• Distinction between clonal MPNs and reactive/secondary thrombocytosis.
• Information necessary to classify a patient as "triple-negative" if JAK2, CALR, and MPL mutations are all absent.
• The presence of a frameshift mutation leading to a novel basic C-terminal peptide.
• Loss of the acidic calcium-binding domain and the KDEL endoplasmic reticulum retention signal.
• Activation status of the thrombopoietin receptor (MPL) signaling cascade.
• Prognostic risk category based on mutation type (Type 1-like vs. Type 2-like).
• Baseline molecular status prior to initiating cytoreductive or targeted therapies.
• Clonal evolution or emergence of secondary mutations during disease progression.
• Genetic markers suitable for monitoring minimal residual disease (MRD).
• Eligibility for clinical trials evaluating novel targeted therapies for CALR-mutant MPNs.
• Distinction between primary myelofibrosis and secondary myelofibrosis (post-ET or post-PV).
• Correlation with bone marrow histological features, such as megakaryocyte morphology.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing accurate and timely molecular diagnostic results. Due to the complex nature of DNA extraction, PCR amplification, and fragment analysis or sequencing, the turnaround time for the CALR Mutation (Exon 9 Mutation) (Form NIBD) at Chughtai Lab is typically 7 to 10 working days. Once the analysis is completed, the report undergoes a rigorous multi-tier review process by consultant molecular pathologists and hematologists to ensure absolute clinical accuracy.

Patients and referring physicians can access the diagnostic reports conveniently through multiple digital channels. An automated SMS notification is sent to the patient's registered mobile number as soon as the report is finalized. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website or via the user-friendly Chughtai Lab Mobile App. Physical copies of the reports can also be collected from any Chughtai Lab medical center or home-delivered upon request.

CALR Mutation (Exon 9 Mutation) (Form NIBD) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CALR Exon 9 Mutation Status	Mutation Not Detected (Wild-type CALR)	Mutation Detected (Somatic indel present)
Mutation Subtype	Not Applicable	Type 1 (52-bp deletion) or Type 2 (5-bp insertion) or atypical variant
Allelic Burden (%)	0% (No mutant alleles)	Detectable mutant allele fraction (ranges from 1% to >50%)
JAK2 V617F Co-status	Typically Negative (Mutually exclusive)	Rarely co-existing; usually negative in CALR-positive cases
MPL Mutation Co-status	Typically Negative (Mutually exclusive)	Negative in the vast majority of CALR-positive cases
Clinical Correlation (ET)	Normal megakaryocyte morphology	Megakaryocytic hyperplasia, persistent thrombocytosis
Clinical Correlation (PMF)	No significant bone marrow fibrosis	Reticulin/collagen fibrosis, osteosclerosis, splenomegaly
Prognostic Category	Standard baseline risk	Type 1 associated with better survival; Type 2 associated with higher platelet counts

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for CALR Mutation (Exon 9 Mutation) (Form NIBD)?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified consultant pathologists and geneticists with extensive experience in hematological malignancies.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate care throughout the testing process.
• Quality Diagnostic Services: Chughtai Lab adheres to strict international quality control standards, ensuring highly reproducible and clinically reliable molecular results.
• Professional Reporting: Our reports are structured to provide clear, actionable clinical insights, facilitating seamless decision-making for oncologists and hematologists.
• Modern Diagnostic Approach: We utilize advanced molecular platforms, including high-resolution fragment analyzers and next-generation sequencing, to detect even low-level mutant clones.
• Comfortable Environment: Our nationwide network of collection centers offers clean, hygienic, and professional environments for specimen collection.
• Convenient Location: With hundreds of collection centers across Pakistan, patients can easily access our services close to their homes.
• Commitment to Accurate Diagnosis: Our collaboration with specialized institutions via the Form NIBD protocol guarantees that complex hematological cases receive the highest level of expert consensus.